기관회원 [로그인]
소속기관에서 받은 아이디, 비밀번호를 입력해 주세요.
개인회원 [로그인]

비회원 구매시 입력하신 핸드폰번호를 입력해 주세요.
본인 인증 후 구매내역을 확인하실 수 있습니다.

회원가입
서지반출
건강한 한국인 자원자에서 말레인산 이르소글라딘의 약동학적 특성에 관한 연구
[STEP1]서지반출 형식 선택
파일형식
@
서지도구
SNS
기타
[STEP2]서지반출 정보 선택
  • 제목
  • URL
돌아가기
확인
취소
  • 건강한 한국인 자원자에서 말레인산 이르소글라딘의 약동학적 특성에 관한 연구
저자명
이승환,임경수,김정렬,김재우,김보형,조주연,윤서현,신상구,장인진,유경상,Lee. Seung-Hwan,Lim. Kyoung-Soo,Kim. Jeong-Ryeol,Kim. Jae-Woo,Kim. Bo-Hyung,Cho. Joo-You
간행물명
臨床藥理學會誌= The journal of Korean Society for Clinical Pharmacology and Therapeutics
권/호정보
2009년|17권 1호|pp.35-43 (9 pages)
발행정보
대한임상약리학회
파일정보
정기간행물|
PDF텍스트
주제분야
기타
이 논문은 한국과학기술정보연구원과 논문 연계를 통해 무료로 제공되는 원문입니다.
서지반출

기타언어초록

Background: Irsogladin maleate, increasing gastric mucosal blood flow and cAMP in mucosal epithelial cells, is being marketed for the treatment of gastric ulcer and gastritis. The object of this study was to evaluate the pharmacokinetic characteristics and safety profiles of irsogladin maleate in Koreans. Methods: An open-label, dose-escalation, parallel group study was conducted in 28 healthy male Korean volunteers. Irsogladin maleate was administered as a single dose of 4 mg (n=16), 8 mg (n=6) or 16 mg (n=6). Serial blood samples for pharmacokinetic analysis were taken over 504 h. Plasma concentration of irsogladin was measured by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters were determined using noncompartmental methods. Laboratory tests, ECGs, vital signs and physical examinations were performed for clinical safety evaluation. Results: Maximum observed irsogladin plasma concentration ($C_{max}$) (mean $pm$ SD) of 4 mg, 8 mg and 16 mg dosage group were $82.9;{pm};12.5{mu};g/L$, $161.4;{pm};25.9;{mu}g/L$ and $292.6;{pm};51.2;{mu}g/L$, respectively. Area under the plasma concentration versus time curve from dosing to the last quantifiable concentration ($AUC_{last}$) of three dosage groups were $12694.4;{pm}2906.2;{mu}g;{ast}h/L$, $24970.0;{pm};5253.8;{mu}g;{ask}h/L$,$47125.3;{pm};8676.7;{mu}g;{ast}h/L$, respectively. Apparent clearance ($0.30;{pm};0.07L/H$, $0.31;{pm};0.10;L/H$, $0.31;{pm};0.06;L/H$, respectively) was unaffected by dosage. The 95% CI of slope of Dose-$C_max$ and Dose-$AUC_{last}$ linear regression were 15.4-19.6 and 2485.2-3262.0. All adverse events reported were mild and no clinically significant abnormalities of safety evaluation were observed. Conclusions: The pharmacokinetic characteristics of Irsogladin maleate after single dose dministration was explored in healthy Korean volunteers. Irsogladin maleate displayed linear plasma pharmacokinetics over the dose range 4-16 mg. Irsogladin maleate was well tolerated after single dose administration in Koreans.